Riad Sherif, CEO of Oculis, gives a company update on clinical trials, financing and other items in the pipeline

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.

Related Videos

View All

Related Content

4D Molecular Therapeutics announces FDA clearance of IND application for 4D-150 genetic medicine for the treatment of DME

February 3rd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Novel gene therapy shows promise for treating multiple eye diseases

February 3rd 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Harrow announces permanent, product-specific J-Code for chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia

February 2nd 2023

Orbis announces 3-year partnership with HOYA Vision Care

February 2nd 2023

4D Molecular Therapeutics announces FDA clearance of IND application for 4D-150 genetic medicine for the treatment of DME

February 3rd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Novel gene therapy shows promise for treating multiple eye diseases

February 3rd 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Harrow announces permanent, product-specific J-Code for chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia

February 2nd 2023

Orbis announces 3-year partnership with HOYA Vision Care

February 2nd 2023

4D Molecular Therapeutics announces FDA clearance of IND application for 4D-150 genetic medicine for the treatment of DME

February 3rd 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Novel gene therapy shows promise for treating multiple eye diseases

February 3rd 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Harrow announces permanent, product-specific J-Code for chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia

February 2nd 2023

Orbis announces 3-year partnership with HOYA Vision Care

February 2nd 2023

Related Content

---

4D Molecular Therapeutics announces FDA clearance of IND application for 4D-150 genetic medicine for the treatment of DME

Article

---

Commercial real estate and your practice, part two with Colin Carr

Podcast

---

Novel gene therapy shows promise for treating multiple eye diseases

Article

---

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcast

---

Harrow announces permanent, product-specific J-Code for chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia

Article

---

Orbis announces 3-year partnership with HOYA Vision Care

Article